Zobrazeno 1 - 10
of 13
pro vyhledávání: '"D. J. Sleep"'
Publikováno v:
The Journal of urology. 164(2)
The severity of lower urinary tract symptoms associated with benign prostatic enlargement correlates poorly with bladder outlet obstruction. Since urodynamic studies are presumed to be relatively complex, invasive and not cost-effective, they are not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c3ec660fa9cdad045b0f9248ea01081f
https://pubmed.ncbi.nlm.nih.gov/10893581
https://pubmed.ncbi.nlm.nih.gov/10893581
Autor:
Joel B. Nelson, Joseph L. Chin, Claude Schulman, P. Hintzman, Michael A. Carducci, W. Love, D. J. Sleep, J. Steinberg, M. Dawson, Jiang Qian
Publikováno v:
Journal of Clinical Oncology. 25:5018-5018
5018 Introduction: Atrasentan is a potent oral, selective endothelin A receptor antagonist with biological activity in patients with HRPC. This randomized phase III trial of atrasentan vs placebo was conducted in 941 men with nonmetastatic HRPC whose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66b05bfa14ba55b2781816ec8d827a01
https://doi.org/10.1200/jco.2007.25.18_suppl.5018
https://doi.org/10.1200/jco.2007.25.18_suppl.5018
Publikováno v:
Journal of Clinical Oncology. 24:4566-4566
4566 Background: Prostate-specific antigen doubling time (PSADT) is used to monitor progression after primary therapy for prostate cancer. Increasingly in this population, PSADT is an efficacy measure in therapeutic trials, many of which are uncontro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d60a213e93f955efb41eb76afcda965
https://doi.org/10.1200/jco.2006.24.18_suppl.4566
https://doi.org/10.1200/jco.2006.24.18_suppl.4566
Autor:
Sarah Yenser, Cassandra Moore, T. Torain, Herbert Hurwitz, Jon P. Gockerman, A. Garcia Turner, Daniel J. George, D. J. Sleep, Patricia Creel, William P. Petros
Publikováno v:
Journal of Clinical Oncology. 24:14504-14504
14504 Background: Docetaxel is first-line standard treatment for metastatic HRPC. New combinations with targeted therapies may improve clinical responses. . Atrasentan is an endothelin receptor A (ETA) inhibitor with an IC50 in the pM range. Clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3181576947830e6207a82c9e8a9ded90
https://doi.org/10.1200/jco.2006.24.18_suppl.14504
https://doi.org/10.1200/jco.2006.24.18_suppl.14504
Publikováno v:
Journal of Clinical Oncology. 24:4630-4630
4630 Background: Hormone-refractory prostate cancer (HRPC) metastasizes most commonly to bone. Treatment of advanced HRPC patients focuses on alleviating bone pain that afflicts 85% of patients. New therapies are needed that not only prolong survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53c3b64758595340cb1be97b6108f637
https://doi.org/10.1200/jco.2006.24.18_suppl.4630
https://doi.org/10.1200/jco.2006.24.18_suppl.4630
Autor:
Nicholas J. Vogelzang, Claude Schulman, Fred Saad, Michael A. Carducci, D. J. Sleep, David P. Dearnaley, Jeffrey D. Isaacson, Joel B. Nelson
Publikováno v:
Journal of Clinical Oncology. 23:4563-4563
4563 Background: Atrasentan (Xinlay), a selective endothelin-A receptor antagonist, has been studied in 2 randomized placebo controlled studies of men with metastatic hormone-refractory prostate ca...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f0a4221ed4262c72b680df5e1f2131e
https://doi.org/10.1200/jco.2005.23.16_suppl.4563
https://doi.org/10.1200/jco.2005.23.16_suppl.4563
Publikováno v:
Journal of Clinical Oncology. 23:8095-8095
8095 Background: The relationship between quality of life (QoL) and morbidity and mortality in metastatic hormone-refractory prostate cancer (M+HRPC) remains unclear. The role of QoL as a predictor...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88235776725ee95611ed0ce327f18cbe
https://doi.org/10.1200/jco.2005.23.16_suppl.8095
https://doi.org/10.1200/jco.2005.23.16_suppl.8095
Publikováno v:
Journal of Clinical Oncology. 22:4655-4655
4655 Background: Bone alkaline phosphatase (BAP) has been validated as a potential predictor of survival in hormone-refractory prostate cancer (HRPC) patients. Phase 2 results show that atrasentan,...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8d5c0379ce2b2e530986560d1e32aaf
https://doi.org/10.1200/jco.2004.22.90140.4655
https://doi.org/10.1200/jco.2004.22.90140.4655
Publikováno v:
Journal of Clinical Oncology. 22:4688-4688
4688 Background: Markers of osteoblastic activity, in particular bone alkaline phosphatase (BAP), increase in hormone refractory prostate cancer (HRPC) patients. BAP has been shown to be as valuabl...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be3129c74b8e3f10f0a4e1dfdd2325a9
https://doi.org/10.1200/jco.2004.22.90140.4688
https://doi.org/10.1200/jco.2004.22.90140.4688
Autor:
David P. Dearnaley, Claude Schulman, Jeffrey D. Isaacson, D. J. Sleep, Fred Saad, S. M. Hulting, Joel B. Nelson, P. Nisen, Michael A. Carducci, A. R. Allen
Publikováno v:
Journal of Clinical Oncology. 22:4508-4508
4508 Background: In earlier trials, atrasentan, a potent, selective, oral endothelin A receptor antagonist, significantly delays time to disease progression (TTP) in a per-protocol group of hormone...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed32356fe5d2c1a41bd102f0fd91eab8
https://doi.org/10.1200/jco.2004.22.90140.4508
https://doi.org/10.1200/jco.2004.22.90140.4508